Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01783054 · ClinicalTrials.gov registry record · Early Phase 1

Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas

A Early Phase 1 study, sponsored by Medical University of South Carolina.

Terminated
Registry status
Early Phase 1
Development phase
2
Enrollment target

NCT01783054 is a Early Phase 1 study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 2 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01783054, a Early Phase 1 study, was terminated before completion, sponsored by Medical University of South Carolina.

TERMINATED
Registry status
Early Phase 1
Development phase
2 participants
Enrollment target

Study Summary

This study is for adult patients with adenocarcinoma of the pancreas. The purpose of this research study is to evaluate the safety and effectiveness of the drugs Gemcitabine and Abraxane in the treatment of adenocarcinoma of the pancreas before surgery. Subjects will have screening tests to determine if he or she is eligible to participate in this study.

Interventions

  • DRUG Chemotherapy
  • PROCEDURE Surgery
  • GENETIC Genetic Expression

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2012-07
Phase Early Phase 1

What the Registry Record Tells You About NCT01783054

The ClinicalTrials.gov registry entry for NCT01783054 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Chemotherapy is the first listed.

NCT01783054 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01783054 about?

NCT01783054 is a clinical study titled "Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas". This study is for adult patients with adenocarcinoma of the pancreas. The purpose of this research study is to evaluate the safety and effectiveness of the drugs Gemcitabine and Abraxane in the treatment of adenocarcinoma of the pancreas before surgery. Subjects will have screening tests to determin...

What is the current status of trial NCT01783054?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2012-07.

What interventions are being tested in trial NCT01783054?

The interventions under investigation include: Chemotherapy (DRUG), Surgery (PROCEDURE), Genetic Expression (GENETIC).

Who is sponsoring clinical trial NCT01783054?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.